Latest Neuroprotection Stories
Neuronascent, a small-molecule central nervous system drug discovery company, has received funding from multiple sources to further the development of its neurogenic compounds targeting Alzheimer's disease, depression and ischemia.
CLARKSVILLE, Md., Oct. 13 /PRNewswire/ -- Neuronascent, Inc. (http://www.neuronascent.com/) announced today that the Company has received funding from multiple sources to further the development of its novel, neurogenic compounds targeting Alzheimer's disease, depression and ischemia.
U.S. and Japanese medical scientists say they've found giving rats a certain hormone immediately after a heart attack significantly reduced coronary damage.
WESTON, Mass., Oct. 2 /PRNewswire/ -- Weston Medical Publishing today announced publication of the first issue of Journal of Neurodegeneration and Regeneration.
German scientists say a protein hormone used to increase blood production in medical treatments and boost athletic performance might also improve memory.
Neurologix, a biotechnology company engaged in the development of gene therapies for the brain and central nervous system, and Aegera Therapeutics, a private clinical stage company focused on oncology and neuropathic pain, have executed an exclusive license agreement.
Biovail Corporation has appointed Neil Sussman as vice president of neurologic and psychiatric development of Biovail Technologies. Dr Sussman brings a wealth of business and academic experience in the field of neurology and other central nervous system (CNS) disorders to Biovail.
Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced the appointment of Dr. Neil M. Sussman as Vice-President, Neurologic and Psychiatric Development of Biovail Technologies, Ltd. The appointment is effective immediately. Dr.
CHICAGO, July 30 /PRNewswire-FirstCall/ -- ANAVEX Life Sciences Corp.
By Mercier, Marie Le Mathieu, Veronique; Haibe-Kains, Benjamin; Bontempi, Gianluca; Mijatovic, Tatjana; Decaestecker, Christine; Kiss, Robert; Lefranc, Florence Abstract Galectin (Gal) 1 is a hypoxia-regulated proangiogenic factor that also directly participates in glioblastoma cell migration.